
Am J Psychiatry 162:386-388, February 2005
© 2005 American Psychiatric Association
Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients
Lawrence E. Adler, M.D.,
Ellen M. Cawthra, R.N.,
Kara A. Donovan, M.P.H.,
Josette G. Harris, Ph.D.,
Herbert T. Nagamoto, M.D.,
Ann Olincy, M.D., and
Merilyne C. Waldo, Ph.D.
OBJECTIVE: Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the -7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential. METHOD: Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug. RESULTS: There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment (ondansetron: mean=41.4%, SD=39.7%; placebo: mean=80.2%, SD=21.3%). CONCLUSIONS: Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics.
This article has been cited by other articles:

|
 |

|
 |
 
D. L. Braff, R. Freedman, N. J. Schork, and I. I. Gottesman
Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder
Schizophr Bull,
January 1, 2007;
33(1):
21 - 32.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant, and N. R. Swerdlow
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Schizophr Bull,
January 1, 2007;
33(1):
69 - 94.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Potter, A. Summerfelt, J. Gold, and R. W. Buchanan
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Schizophr Bull,
October 1, 2006;
32(4):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|